What Is 5-Amino-1MQ?

Published August 2026 · Patriot Labs Research Team · ~11 min read

First, the correction: this is not a peptide

5-Amino-1MQ is sold on peptide sites, discussed in peptide forums, and stocked next to peptide vials — including ours. None of that makes it a peptide. A peptide is a chain of amino acids joined by amide bonds between one residue's carboxyl group and the next residue's amino group. That is the whole definition, and it is what every compound in our peptides primer has in common.

5-Amino-1MQ has no amino acids in it and no peptide bonds. It is a single small aromatic ring system with two substituents. Chemically it has more in common with a dye or a nucleotide base analogue than with BPC-157 or ipamorelin. It is a small molecule, in the ordinary medicinal-chemistry sense of that phrase.

The distinction is not pedantry. Peptides are large, fragile, and generally do their work by binding the outside of a receptor. Small molecules are compact, comparatively robust, and often work by slipping into an enzyme's active site and occupying it. 5-Amino-1MQ is squarely in the second category: it is an enzyme inhibitor, and the handling, the stability profile, the mechanism and the kind of evidence that would be needed to support it all follow from that.

The research-chemical market is organised by who buys things, not by what things are. Metabolic researchers who buy peptides also buy 5-Amino-1MQ, so vendors shelve them together. That is a distribution fact, not a chemical one.

What 5-Amino-1MQ is, chemically

The full name is 5-amino-1-methylquinolinium. Read from the inside out, that name is a complete structural description.

Quinoline is a bicyclic aromatic heterocycle — a benzene ring fused to a pyridine ring, sharing an edge. Quinolinium means the nitrogen of that pyridine ring has been alkylated, which puts a formal positive charge on the nitrogen and makes the molecule a permanent cation rather than a neutral base. The 1-methyl prefix says what did the alkylating: a methyl group on ring nitrogen, position 1. The 5-amino prefix says there is a primary amine (–NH₂) on carbon 5, over on the fused benzo ring.

The permanent positive charge is the interesting design feature. The natural substrate of NNMT is nicotinamide, and the natural product of the reaction is 1-methylnicotinamide — itself a methylated, positively charged pyridinium. 5-Amino-1MQ is recognisably a mimic of that chemistry: a methylated nitrogen heterocycle carrying a fixed cationic charge, which is why it competes with nicotinamide for the enzyme's substrate site rather than binding somewhere else.

Permanent cations are usually poor at crossing membranes, which is a real problem for an inhibitor whose target sits inside the cell. The medicinal-chemistry work that produced this compound was explicitly about that trade-off. Neelakantan and colleagues reported in Biochemical Pharmacology in 2018 that methylquinolinium scaffolds bearing primary amine substitutions combined high membrane permeability with selectivity for NNMT — the amine at position 5 is not decoration, it is the substituent that made the scaffold usable in cells and in animals.

5-Amino-1MQ at a glance

What NNMT does, and why anyone wants to block it

Nicotinamide N-methyltransferase catalyses one reaction. It takes a methyl group from S-adenosylmethionine (SAM) and attaches it to the ring nitrogen of nicotinamide. Two products come out: 1-methylnicotinamide, and S-adenosylhomocysteine (SAH), the demethylated remains of the cofactor. The 2024 Frontiers in Pharmacology review of NNMT states the reaction in exactly those terms — NNMT catalyses methylation of nicotinamide using SAM as the methyl donor, forming SAH and methylnicotinamide.

Conventionally this is described as a clearance reaction: methylation converts nicotinamide into something the kidney can excrete. But the reaction consumes two metabolites that cells are otherwise careful with, and that dual consumption is the entire rationale for inhibiting the enzyme.

First drain: nicotinamide. Nicotinamide is not merely a waste product to be disposed of. It is the entry point of the salvage pathway that regenerates NAD⁺ — the cofactor that NAD⁺-consuming enzymes such as sirtuins and PARPs chew through continuously. The Frontiers review puts the consequence bluntly: once nicotinamide has been methylated by NNMT, it is no longer available for NAD⁺ generation via the salvage pathway. Every molecule the enzyme processes is a molecule the salvage pathway does not get.

Second drain: SAM. S-adenosylmethionine is the universal methyl donor. Essentially every biological methylation — DNA, histones, phospholipids, small-molecule metabolites — draws on the same SAM pool. A methyltransferase running at high flux is therefore not a local event; it is competition for a shared resource. The 2014 Nature report that first put NNMT on the metabolic map made this point structurally, noting that SAM also supplies propylamine for polyamine biosynthesis and methyl groups for histone methylation, and that knocking down the enzyme raised adipose SAM and NAD⁺ levels together while changing histone H3 lysine 4 methylation in adipose tissue.

So the argument for an NNMT inhibitor is not “block a bad enzyme.” It is narrower and more interesting than that: in a tissue where NNMT flux is high, the enzyme is spending two scarce currencies at once, and inhibiting it is proposed to return both to circulation. Whether that actually produces a durable, useful effect is a separate question, and the literature answering it is thinner than the mechanism is elegant.

Why the work keeps coming back to fat tissue

NNMT is not evenly distributed. Reviews of the enzyme describe it as predominantly localised in adipose tissue and liver, with elevated expression reported in the liver and white adipose tissue of obese and diabetic rodent models. That tissue bias is why adipocyte biology, rather than, say, neurology, became the centre of gravity for this compound class.

The paper that started it was not about an inhibitor at all. In 2014, Kraus and colleagues reported in Nature that when they compared white adipose tissue from adipose-specific Glut4-knockout mice against adipose-specific Glut4-overexpressing mice, Nnmt was the most strongly reciprocally regulated gene on the array — a result nobody was looking for. They then reported that NNMT expression was increased in white adipose tissue and liver of obese and diabetic mice, and that knocking Nnmt down in those two tissues protected the animals against diet-induced obesity by increasing cellular energy expenditure. The mechanistic chain they proposed ran through raised adipose SAM and NAD⁺, altered histone H3K4 methylation, and increased polyamine flux, with adipocyte oxygen consumption rising in a manner dependent on the polyamine enzymes ODC, SSAT and PAO.

That is a knockdown study in mice, using antisense-style genetic suppression — not a compound. The pharmacology came afterwards, and 5-Amino-1MQ belongs to the class of molecules built to reproduce a genetic result with a drug-like tool. This is a common and honourable pattern in target validation, but it is worth naming, because the strength of the 2014 genetic result is frequently transferred wholesale onto the small molecule in marketing copy. They are different experiments.

Readers coming to this compound from the metabolic side of the catalogue should note that it does not resemble the incretin-style compounds discussed in our guide to peptides studied in weight and metabolic models. Those act on receptors from outside the cell. NNMT inhibition is an intracellular enzymatic intervention with a completely different logic, and the two literatures should not be blended.

The NAD⁺ connection, stated carefully

The NAD⁺ framing is where most of the enthusiasm around 5-Amino-1MQ comes from, and it is also where the reasoning most often gets sloppy. It is worth separating what is established biochemistry from what is a proposal under study.

Established: nicotinamide is a substrate for both NAMPT (which begins salvage back to NAD⁺) and NNMT (which methylates it into a dead end for that purpose). Those two enzymes draw on the same pool. This is textbook pathway topology, and it is the reason the connection is drawn at all.

Proposed and under study: that pharmacologically inhibiting NNMT meaningfully increases NAD⁺ availability in a tissue, and that the increase is large enough and sustained enough to drive the downstream effects researchers are interested in. Kraus and colleagues reported increased NAD⁺ with genetic knockdown in mouse adipose tissue, and the 2018 inhibitor paper reported increased intracellular NAD⁺ alongside suppressed lipogenesis. Those are real findings, but they are findings in specific tissues in specific rodent and cell models, not a general rule about NAD⁺ status.

It is also worth being clear about the difference in strategy. Direct NAD⁺ precursor work — the subject of our separate guide to NAD⁺ in research, and the reason NAD⁺ is stocked as its own item — approaches the pool by adding material to it. NNMT inhibition approaches it by reducing a drain on it. These are not the same experiment, they do not produce the same evidence, and a result from one does not transfer to the other. Anyone reasoning about the NAD⁺ literature, including the sirtuin-adjacent claims that show up in longevity-oriented research, should keep those two arms separate.

What the research actually is

Being specific about model systems is the fastest way to see the shape of this literature. Almost all of it is cell culture and mice.

Diet-induced obese mice. The 2018 Biochemical Pharmacology report from Neelakantan and colleagues described methylquinolinium-scaffold NNMT inhibitors as selective and membrane-permeable, and reported reduced body weight and white adipose mass in diet-induced obese mice, with plasma cholesterol also reduced and food intake unaffected. A 2022 Scientific Reports paper from an overlapping group combined 5-amino-1-methylquinolinium with a reduced-calorie diet in male C57BL/6J mice previously maintained on high-fat and Western diets, and reported that the combination produced weight and adiposity loss faster than diet alone, alongside a distinct caecal microbiome signature — decreased Erysipelatoclostridium, increased Lactobacillus, with 6–8 animals per group.

Aged mice. A 2024 Scientific Reports paper treated 22-month-old mice with an NNMT inhibitor, intensive exercise, or both, to 24 months of age, and reported that inhibitor-treated sedentary aged mice showed roughly 40% greater grip strength than sedentary controls, that exercised aged mice showed about 20%, and that the two interventions were additive at around 60%. The compound used was 5-amino-1-methylquinolinium. The same group had earlier reported, in Biochemical Pharmacology in 2019, on an NNMT inhibitor and senescent muscle stem cells in aged skeletal muscle.

Cultured cells, mostly oncology. A substantial share of the records naming this compound are not metabolic at all. A 2021 report in the Journal of Obstetrics and Gynaecology described 5-amino-1-methylquinolinium inhibiting HeLa cervical cancer cell proliferation in a concentration- and time-dependent manner with reduced phospho-Akt and SIRT1 protein. A 2024 paper in the Journal for ImmunoTherapy of Cancer used 5-Amino-1MQ iodide in urothelial bladder cancer models, reporting reduced tumour growth in that setting. A 2025 report in Investigative Ophthalmology & Visual Science used NNMT silencing and pharmacological antagonism in orbital fibroblasts from Graves' orbitopathy tissue.

That distribution matters. If you search for this compound expecting a deep metabolic literature, what you actually find is a handful of metabolic papers from a small number of connected groups, a scattering of oncology cell-culture work, and a growing stack of review articles that cite the same primary papers back and forth. A Europe PMC search for the exact term “5-amino-1MQ” returned 9 records when run for this guide. Broadening the search to the enzyme rather than the compound returns far more — but most of that is NNMT biology, not this molecule.

What the evidence does not establish

This is the section that matters most, because the gap between what has been shown and what is claimed for this compound is unusually wide.

There is no human clinical data. This is not a hedge, it is the state of the field. The 2024 Frontiers in Pharmacology review of NNMT as a therapeutic target for metabolic syndrome states directly that clinical trials focusing on NNMT have not been documented. Nothing retrieved for this guide contradicts that. Every effect described above was measured in a dish or in a rodent.

The foundational result is genetic, not pharmacological. The 2014 Nature paper used knockdown of Nnmt expression in mouse tissue. A small molecule that inhibits enzyme activity is not the same intervention: it acts on a different timescale, achieves partial rather than near-complete suppression, distributes to tissues the knockdown never touched, and can have off-target activity a knockdown cannot. Treating the 2014 result as though it were an inhibitor result is the single most common error in writing about this compound.

The primary metabolic work comes from a narrow set of groups. The 2018 inhibitor paper, the 2019 muscle stem cell paper, the 2022 microbiome paper and the 2024 aged-mouse paper share authors and institutional lineage. Consistency within a research programme is not the same as independent replication, and independent replication of the metabolic mouse findings is not something this guide was able to locate.

Sample sizes are small and endpoints are rodent-specific. The 2022 microbiome study reported 6–8 animals per group. Grip strength in a 24-month-old mouse is a legitimate laboratory endpoint; it is not a claim about anything in a person, and it does not translate through simple analogy.

The mechanism has plausible failure modes that have not been ruled out. Inhibiting a methyltransferase raises the SAM pool available to every other methyltransferase in the cell, and the 2014 work itself reported altered histone H3K4 methylation. A chronic, global shift in methyl-donor availability is a large intervention with epigenetic reach, and the long-term consequences of it are not characterised in the retrieved literature. Separately, 1-methylnicotinamide — the product that inhibition suppresses — is not inert; a 2025 review of NNMT in cardiovascular disease describes it as having a complex duality with both pathogenic and protective effects reported. Suppressing its formation is therefore not unambiguously subtractive.

Tissue selectivity is unaddressed. NNMT is elevated in numerous tumour types, which is why so much of the compound literature is oncological. An intervention that alters NAD⁺ and SAM handling across liver, adipose, muscle and tumour tissue simultaneously is not a targeted one, and the retrieved work does not resolve what that breadth implies.

Popularity is not evidence. 5-Amino-1MQ is marketed far more heavily than a nine-record compound literature can support. Where a vendor's confidence outruns the citation count by that margin, the confidence is coming from somewhere other than the data.

Bench notes: it does not behave like a peptide

Because 5-Amino-1MQ arrives from a peptide supplier, it is easy to assume the peptide playbook applies. Some of it does not, and the differences follow directly from the chemistry.

Peptides are conformational molecules. Their degradation routes — deamidation, oxidation of methionine and tryptophan, disulfide scrambling, aggregation, proteolysis — are the subject of a separate guide on how peptides degrade, and essentially none of those routes apply to a small aromatic heterocycle. A quinolinium salt has no backbone to cleave and no fold to lose. As a class, small molecule salts of this kind are markedly more robust than lyophilised peptides, and their failure modes are different ones — hygroscopicity, photosensitivity of the aromatic system, counter-ion and purity questions.

Two practical consequences follow. Identity and purity should be established from the certificate of analysis rather than assumed — a small molecule is characterised by different analytics than a peptide, so the reasoning in our guide to reading a COA transfers even though the specific methods do not. And solubility behaviour differs: a permanently charged salt does not have the same solvent relationship as a lyophilised peptide cake, so procedures written for peptides should not be applied to it unexamined.

None of this is a protocol, and this guide does not provide one. It is a caution against pattern-matching a small molecule onto peptide habits because it happened to be shipped in the same box.

Frequently asked questions

Is 5-Amino-1MQ a peptide? No. It is a small organic molecule — 5-amino-1-methylquinolinium, a substituted quinolinium salt. It contains no amino acids and no peptide bonds. It is stocked alongside research peptides for commercial reasons, not chemical ones.

What does the enzyme NNMT actually do? Nicotinamide N-methyltransferase transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide and S-adenosylhomocysteine. Reviews of the enzyme note that once nicotinamide has been methylated it is no longer available for NAD⁺ regeneration through the salvage pathway.

Why is 5-Amino-1MQ associated with adipose tissue research? NNMT is reported to be concentrated in liver and white adipose tissue, and its expression is described as elevated in obese and diabetic rodent models. The 2014 Nature report that Nnmt knockdown in white adipose tissue and liver protected mice against diet-induced obesity is the origin of most later interest in blocking the enzyme pharmacologically.

Is there human clinical data on 5-Amino-1MQ? No published controlled human trials were located. A 2024 Frontiers in Pharmacology review of NNMT as a metabolic target states plainly that clinical trials focusing on NNMT have not been documented. The published record is cell culture and rodent work.

Is 5-Amino-1MQ approved for human use? No. 5-Amino-1MQ is not an approved drug in any jurisdiction known to us, and material supplied by Patriot Labs is sold strictly for in-vitro research and laboratory use only. It is not for human or veterinary consumption.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes peptide chemistry and published research in general terms; it is not medical advice, does not describe how to use any product, and the references cited do not constitute a product claim.